Translational investigation of a lithium mimetic for treatment of bipolar disorder
Lead Research Organisation:
University of Oxford
Department Name: Pharmacology
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Organisations
Publications
Grant Churchill (Author)
(2013)
A safe lithium mimetic? The inositol depletion hypothesis rescues an experimental drug for bipolar disorder
in Biochemist
Singh N
(2012)
Cloning, expression, purification, crystallization and X-ray analysis of inositol monophosphatase from Mus musculus and Homo sapiens.
in Acta crystallographica. Section F, Structural biology and crystallization communications
Singh N
(2013)
A safe lithium mimetic for bipolar disorder.
in Nature communications
| Title | TREATMENT OF BIPOLAR DISORDER |
| Description | The invention relates to sulphur- and/or selenium-containing compounds that can inhibit the enzyme inositol monophosphatase (IMPase), and which can be used in treating conditions that are treatable through inhibition of this enzyme, such as bipolar disorder, the compounds having a structure of Formula I, or is a pharmaceutically acceptable salt thereof; Formula I; in which: E is S or Se and each of phenyl rings A and B is optionally substituted with one or more substituents, in which each substituent is selected independently from: (1) a halogen, which is preferably selected from F, Cl and Br; (2) C1-C4 alkyl, such as C1-C2 alkyl or C1 alkyl, optionally substituted with one or more halogen atoms, each of which is preferably selected from F, Cl and Br; and (3) C1-C4 alkoxy, such as C1-C2 alkoxy or C1 alkoxy; optionally substituted with one or more halogen atoms, each of which is preferably selected from F, Cl and Br. |
| IP Reference | WO2012107735 |
| Protection | Patent / Patent application |
| Year Protection Granted | 2012 |
| Licensed | Yes |
| Impact | It has fostered collaborative research on the drug ebselen. Funding (£1.4 M) from the MRC was secured for a study of impulsiveness in both a rat model and this will be translated into humans in an experimental medicine study. Funding from a Bipolar and Schizophrenia charity in the US called The Stanley Foundation has awarded ~£800,000 to fund a Phase 2, investigator-led efficacy trial for ebselen in bipolar disorder in Oxford. An American biotech company, Sound Pharmaceuticals, took a 3-year option, and has now (2022 December) has licensed the patent for £600k). |